RhumbLine Advisers’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

RhumbLine Advisers’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-13,585	Closed	-$1.79M	–	3052
2020 Q4	$1.79M	Sell	13,585 -1,894	-12%	-$167K	﹤0.01%	1903
2020 Q3	$782K	Sell	15,479 -2,286	-13%	-$103K	﹤0.01%	2085
2020 Q2	$847K	Buy	17,765 +144	+0.8%	+$6.7K	﹤0.01%	2114
2020 Q1	$863K	Buy	17,621 +237	+1%	+$12.1K	﹤0.01%	1942
2019 Q4	$998K	Buy	17,384 +729	+4%	+$36.1K	﹤0.01%	2087
2019 Q3	$599K	Sell	16,655 -75	-0.4%	-$2.93K	﹤0.01%	2254
2019 Q2	$520K	Sell	16,730 -2,235	-12%	-$60.6K	﹤0.01%	2346
2019 Q1	$445K	Buy	+18,965	New	+$304K	﹤0.01%	2375

RhumbLine Advisers's EIDX Position: Q1 2021 in Review

RhumbLine Advisers sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 13,585 shares — an estimated $1.79M sold.

RhumbLine Advisers first reported a position in EIDX in Q1 2019 and held it in 8 quarters. The position peaked at $1.79M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

RhumbLine Advisers reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
RhumbLine Advisers sold 13,585 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $1.79M.
RhumbLine Advisers first reported a position in Eidos Therapeutics, Inc. Common Stock in Q1 2019 and held it in 8 quarters.
RhumbLine Advisers's Eidos Therapeutics, Inc. Common Stock position peaked at $1.79M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on RhumbLine Advisers's 13F filing for Q1 2021, filed 6 May 2021.